DWDagmar Wilsmann-Theis

Dagmar Wilsmann-Theis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dagmar Wilsmann-Theis has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    S1‐Leitlinie: Therapie der generalisierten pustulösen Psoriasis

    by Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, et al.

    Zusammenfassung: Die S1‐Leitlinie „Therapie der generalisierten pustulösen Psoriasis (GPP)“ ist eine deutsche Leitlinie, die nach den Kriterien der AWMF erstellt wurde. In der Langfassung werden Aspekte wie klinisches Bild, Pathogenese, Diagnose und Differenzialdiagnose, Begleiterkrankungen und Therapien beleuchtet. Ferner wurden dort Therapieempfehlungen für Erwachsene mit GPP verabschiedet. Hierbei wurden sowohl zugelassene Therapien als auch Off‐Label‐Therapien berücksichtigt. Der vorliegende Artikel stellt eine gekürzte Fassung der Leitlinie dar, wobei die Therapieempfehlungen vollständig und ungekürzt aufgeführt werden.

  • Open Access

    Aggressive Plattenepithelkarzinome auf dem Boden eines Lichen ruber mucosae: Bericht über drei Fälle

    by Neda Cramer, Dagmar Wilsmann‐Theis, Michael P. Schön, Jörg Wenzel, Julia Gallwas, Rotraut Mössner

  • Open Access

    Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross‐sectional study

    by Svenja Royeck, Anna Daphne Bamidis, Conrad Weckbecker, Silke C. Hofmann, Sonja Ständer, Stefan W Schneider, Angelika Weigel, Natalija Novak, Dagmar Wilsmann‐Theis, Galina Balakirski

    Summary: Background and objectives: Trust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients. Patients and methods: Cross‐sectional surveys of AD or PSO patients were conducted at two dermatological university centers in Germany. Group differences were analyzed using Mann‐Whitney U and Kruskal‐Wallis tests; associations between trust (6‐point Likert scale: 1 = very high, 6 = none) and demographics, disease severity, pruritus, pain, and quality of life (QoL) using Spearman correlations. All analyses were exploratory. Results: Among 253 AD or PSO patients (median age 53.0 years, interquartile range 36.0–63.0; 43.9% female) median trust in skin care and topical therapies was moderate. AD patients reported significantly higher trust than PSO patients. In AD, trust in skin care correlated with pruritus intensity ( p < 0.001), pain intensity ( p < 0.05), and QoL ( p < 0.001); trust in topical therapy correlated with QoL ( p < 0.01). No significant correlations were observed in PSO. Conclusions: Trust levels were higher in AD than in PSO but tended to decline with increasing disease burden and poorer QoL. Enhancing patient education and shared decision‐making may help improve trust and adherence.

  • Open Access

    S1 Guideline: Therapy of generalized pustular psoriasis

    by Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, et al.

    Summary: The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy. In addition, therapy recommendations for adults with GPP are provided. Both approved and off‐label therapies are considered. The present article is a shortened version of the guideline, whose therapy recommendations are presented in full and without omission.


  • Open Access

    Palmoplantare Pustulose: Entstehung, Differentialdiagnose und Therapie

    by Rotraut Mössner, Tanja Fetter, Robert Sabat, Ulrich Mrowietz, Neda Cramer, Dagmar Wilsmann‐Theis

    Zusammenfassung: Die palmoplantare Pustulose (PPP) ist eine chronisch entzündliche, häufig schmerzhafte Erkrankung mit sterilen Pusteln an Handflächen und Fußsohlen, die die Lebensqualität stark einschränkt. Frauen sind häufiger betroffen als Männer, und Rauchen ist ein bedeutender Provokationsfaktor. Unter Therapie mit Biologika, vor allem TNF‐Antagonisten, kann eine sogenannte paradoxe PPP auftreten. Die PPP ist mit der Psoriasis vulgaris assoziiert und kann mit osteoartikulärer Beteiligung einhergehen. Pathogenetisch beginnt die PPP wahrscheinlich um das Acrosyringium. Die Pusteln bestehen überwiegend aus neutrophilen Granulozyten, die durch von aktivierten Keratinozyten sezernierte chemotaktische Faktoren angelockt werden. Die Entzündung wird durch einen sich selbst verstärkenden Mechanismus aufrechterhalten, an dem Interleukin (IL)‐17, IL‐19 und weitere Mediatoren beteiligt sind. Bei der PPP werden topische Therapien, UV‐Photo‐Therapien, vor allem als topische PUVA‐Therapie (Psoralen plus UVA‐Strahlung), und Systemtherapien eingesetzt. Die systemischen Therapien umfassen konventionelle Medikamente wie Acitretin, Methotrexat, Fumarsäureester und Ciclosporin, neuere small molecules wie Apremilast und Januskinase‐Inhibitoren sowie Biologika. Konventionelle Systemtherapien sind bei der PPP oft nicht ausreichend wirksam und nebenwirkungsbehaftet. Aktuell besitzt von den Systemtherapien nur Acitretin eine Zulassung für die PPP. In den letzten Jahren konnten in placebokontrollierten Studien signifikante Effekte von Apremilast, Brodalumab, Guselkumab und Risankizumab auf die PPP gezeigt werden, und weitere Studien mit topischen und systemischen Januskinase‐Inhibitoren sowie IL17A/F‐ Inhibitoren werden durchgeführt.

  • Open Access

    Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment

    by Rotraut Mössner, Tanja Fetter, Robert Sabat, Ulrich Mrowietz, Neda Cramer, Dagmar Wilsmann‐Theis

    Summary: Palmoplantar pustulosis (PPP) is a chronic inflammatory and often painful disease characterized by sterile pustules on the palms and soles, significantly impairing quality of life. Women are more frequently affected than men, and smoking is a major trigger. Under biologic therapies, especially TNF antagonists, a paradoxical PPP may occur. PPP is associated with psoriasis vulgaris and may be accompanied by osteoarticular involvement. Pathogenetically, PPP likely begins around the acrosyringium, with the pustules consisting almost exclusively of infiltrating neutrophilic granulocytes attracted by chemotactic factors secreted by activated keratinocytes. Inflammation is sustained through a self‐amplifying cytokine network, including interleukin (IL)‐17, IL‐19, and related mediators. Treatment options for PPP include topical treatments, UV‐phototherapies ‐ particularly topical PUVA (Psoralen plus UVA) therapy‐ and systemic therapies. Systemic agents comprise conventional treatments such as acitretin, methotrexate, fumaric acid esters, and ciclosporin, newer small molecules like apremilast and Janus kinase inhibitors, as well as biologics. Conventional systemic therapies are often not sufficiently effective in PPP and associated with side effects. Currently, among systemic therapies, only acitretin is approved for PPP. In recent years, placebo‐controlled studies have demonstrated a significant effect of apremilast, brodalumab, guselkumab and risankizumab on PPP, and further studies with topical and systemic Janus kinase inhibitors as well as IL‐17A/F inhibitors are underway.


  • Open Access

    Aggressive squamous cell carcinomas arising from mucosal lichen planus: A report of three cases

    by Neda Cramer, Dagmar Wilsmann‐Theis, Michael P. Schön, Jörg Wenzel, Julia Gallwas, Rotraut Mössner

  • Open Access

    Disclosing the Overall and Sex‐Related Disease Burden and Treatment Needs of Patients With Anogenital Psoriasis: Results From the Case–Control PsoGen Study

    by Neuza da Silva Burger, Matthias Augustin, Dagmar Wilsmann-Theis, Athanasios Tsianakas, Petra Staubach-Renz, Rachel Sommer

    Purpose: Psoriasis lesions in the anogenital area affect about 33%–63% of the patients at some point in the disease course. Diminished quality of life (QoL), high depression rates, and sexual impairments have been described among patients with anogenital psoriasis, but specific treatment needs of these patients are often neglected in routine healthcare. This study aimed to compare patients with vs. without current anogenital lesions in terms of their sociodemographic and clinical characteristics, patient‐reported outcomes (PROs) of disease burden, and patient‐defined treatment needs/benefits and to identify clinical variables associated with PROs of disease burden. Patients and Methods: The study had a cross‐sectional case–control design. Patients aged ≥ 18 years with psoriasis were consecutively recruited in four German dermatology centers and were assigned to case or control group based on both patients’ and physicians’ reports of current anogenital involvement. PROs included the assessment of QoL impairments, treatment needs/benefits, depression/anxiety, perceived stigmatization, sexual frequency, and relationship/sexual impairments. Physicians assessed the severity of psoriasis and anogenital lesions (PASI and sPGA‐G). Results: Participants were 294 patients with psoriasis, of which 159 (54.1%) had current anogenital lesions. Patients with anogenital lesions had higher disease severity, more comorbidities, but were less often treated with biologics. They also reported more QoL impairments, less treatment benefits, poorer mental health, and more sexual impairments. Specific treatment needs of patients with anogenital psoriasis were related to reducing physical and relationship/sexual impairments. Poorer PROs were explained at 25%–68% by higher disease severity, anogenital lesions, no biologic treatment, higher intensity of itching/burning, and lower frequency and more limitations in sexual activity. Conclusion: Within a patient‐centered approach to dermatology care for psoriasis, clinical decisions, particularly patients’ qualification for treatment with biologic drugs, should consider not only the location, extent, and severity of psoriasis lesions but also patient‐reported symptoms, overall disease burden, and sexual limitations.

  • Open Access

    Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study

    by Svenja Royeck, Anna Daphne Bamidis, Conrad Weckbecker, Silke C. Hofmann, Sonja Ständer, Natalija Novak, Galina Balakirski, Dagmar Wilsmann-Theis

    Introduction Despite the expanding range of approved systemic therapies for atopic dermatitis (AD) and psoriasis (PSO), data on patient preferences remain limited. It is largely unknown whether patients wish to initiate systemic treatment, which route of administration (oral versus subcutaneous) they prefer, or what factors drive their treatment preferences. This study evaluated the desire for systemic therapy among systemic treatment-naïve patients with AD or PSO, including disease-specific influencing factors and preferences for administration routes (subcutaneous injections vs. tablets). Methods Eligible patients with AD or PSO were recruited at two German university hospitals. Questionnaires collected demographic and clinical data, including disease severity, pruritus and pain intensity, quality of life (QoL) impairment, and desire for systemic therapy. Data analysis comprised Mann–Whitney U tests (between-group comparisons), and Spearman correlations (factors influencing therapy desire). Results From 253 recruited patients, systemic treatment-naïve patients with moderate-to-severe disease severity exclusively using topical therapies were selected (56 with AD, 63 with PSO); 77.8% of patients with PSO and 67.9% of patients with AD desired systemic therapy, mainly for superior efficacy, QoL improvement, and pruritus reduction. Administration preferences differed significantly (PSO 57.1% injections; AD 73.7% tablets; p < 0.005). The desire for systemic therapy moderately correlated with pain intensity (ρ = 0.422, p < 0.001) and QoL impairment (ρ = 0.379, p < 0.005) in AD and with male sex in PSO (ρ = 0.347, p < 0.005). Conclusions Most topically treated patients with moderate-to-severe AD or PSO desire systemic therapy, with distinct disease-specific administration preferences.


  • Open Access

    Low satisfaction with medical care among patients with hidradenitis suppurativa: A multicenter study

    by Kerstin Wolk, Giorgia Cugno, Georgios Kokolakis, Sylke Schneider‐Burrus, Dagmar Wilsmann‐Theis, Katharina Assaf, Rotraut Moessner, Christian Kromer, Falk G. Bechara, Nessr Abu Rached, et al.